# Plain Language Summary: Human Cells and Tissues Regulation Update

This bill asks the Food and Drug Administration (FDA) to update and modernize its rules about how human cells, tissues, and cell-based products are handled and sold in the United States. Right now, the FDA has regulations that were written years ago, and this bill essentially tells them it's time to review and refresh those rules to reflect current science and practices.

Here's what this means in practical terms: The FDA oversees products made from human cells and tissues—things like skin grafts for burn victims, bone products for orthopedic surgery, reproductive tissues, and various cellular therapies. These are medical products that doctors use to help patients heal or treat diseases. The current regulations that govern these products haven't kept pace with how the field has evolved. By updating these rules, the FDA can make sure that products are safe and effective while also allowing beneficial new treatments to reach patients more efficiently. This could affect patients waiting for these therapies, manufacturers developing new cell-based treatments, and hospitals and clinics that use these products.

The bill doesn't specify exactly what changes need to happen—that's left to the FDA to figure out through their rule-making process. But the general goal is to modernize outdated regulations so they better match today's science and medical practices, while still protecting patients from unsafe or ineffective products. It's essentially Congress telling the FDA to take a fresh look at rules that have been around for a while and make sure they still make sense.

To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to promulgate rules to update certain regulations relating to human cells, tissues, and cellular and tissue-based products, and for other purposes.

This bill requires the Food and Drug Administration to update its regulations relating to the manufacture of human cells, tissue, and cellular and tissue-based products (HCT/Ps), including an update to the definition of minimal manipulation. (The regulations are commonly referred to as the tissue rules; HCT/Ps that are minimally manipulated and meet other criteria are not regulated as drugs, devices, or biologics and therefore are not subject to premarket review.)